 |
|
Clues to ensuring anti-HIV drugs are taken in Africa
October 23, 2007DURHAM, N.C. - HIV-infected patients in the African country of Tanzania were more likely to stop taking their medications and to fail treatment if they had to pay for the drugs themselves.
According the results of a new study conducted by Tanzanian physicians and Duke University Medical Center researchers, HIV-infected patients who openly discussed their illness were also more likely to fare better.
"Our findings suggest that efforts to provide free medication to HIV-infected patients and to promote social coping may increase the chances that patients will continue taking their medications and therefore have stronger immune systems and live longer," said Habib Ramadhani, M.D., physician at the Kilimanjaro Christian Medical Centre and lead author of a paper appearing early online in the journal Clinical Infectious Diseases. Infectious disease specialists from Duke collaborate with the Kilimanjaro medical center physicians at a clinic in Moshi, Tanzania.
The findings of this and other studies in sub-Saharan African countries should help policy makers and physicians figure out how best to direct and manage the increase in the amount of powerful HIV-fighting drugs that are flowing into the continent, the researchers said. This group of drugs, known generally as anti-retroviral therapy, can suppress the levels of virus in the blood to almost non-detectable levels and prolong life.
In order to better understand the barriers that may keep patients in such economically challenged countries from successfully fighting the disease, the researchers studied 150 HIV-infected patients seen at the Moshi clinic, paying particular attention to how well patients were adhering to their medication regimens and how successfully the levels of virus in the blood was responding to the therapy.
About one in six of the patients reported not taking their medications according to schedule, and the patients more likely to have stopped complying were those who had spent a larger proportion of their time on treatment paying for the antiretroviral medicines themselves. These patients typically used their scant resources on other necessities, such as food and shelter, rather than the medicines, researchers said.
They also found that about one in three patients had increases in the level of virus in the blood consistent with treatment failure, and not surprisingly, the patients who were not taking their drugs were more likely to have treatment failure.
"Another quite interesting finding was that being public about their HIV status was associated with suppression of virus," Ramadhani said. "There still is a substantial stigma associated with HIV in Africa. It is likely that individuals infected with HIV who discussed their disease with friends or family members are likely living in supportive environments that promote adherence."
The researchers also found that the farther away patients were from the clinic, the less likely they would take their drugs as instructed.
"This study has identified critical factors that affect the success of antiretroviral therapy programs in Africa, and we believe that these findings should be incorporated by policy makers into practice," said Duke's John Crump, M.B., Ch.B, who specializes in infectious diseases and international health and is a senior member of the research team. "These drugs, which are known to work, should be free and readily available.
"Structural barriers to care, such as the distance to clinics and especially the burden of patients paying for their medication, must be removed," Crump continued. "Social coping, including the disclosure of HIV status to people to family and friends leads to better adherence to medication and lower rates of treatment failure."
According to Michael H., Merson. M.D., director of the Duke Global Health Institute, "This study nicely illustrates some of the factors that need to be considered in reducing the health disparities between the haves and have nots throughout the world, and the value of exploring ways to eliminate them through a multidisciplinary lens. Reducing costs, increasing access and lessening stigma are all necessary for providing good AIDS treatment."
Duke University Medical Center
The findings of this and other studies in sub-Saharan African countries should help policy makers and physicians figure out how best to direct and manage the increase in the amount of powerful HIV-fighting drugs that are flowing into the continent, the researchers said. This group of drugs, known generally as anti-retroviral therapy, can suppress the levels of virus in the blood to almost non-detectable levels and prolong life.
In order to better understand the barriers that may keep patients in such economically challenged countries from successfully fighting the disease, the researchers studied 150 HIV-infected patients seen at the Moshi clinic, paying particular attention to how well patients were adhering to their medication regimens and how successfully the levels of virus in the blood was responding to the therapy.
About one in six of the patients reported not taking their medications according to schedule, and the patients more likely to have stopped complying were those who had spent a larger proportion of their time on treatment paying for the antiretroviral medicines themselves. These patients typically used their scant resources on other necessities, such as food and shelter, rather than the medicines, researchers said.
They also found that about one in three patients had increases in the level of virus in the blood consistent with treatment failure, and not surprisingly, the patients who were not taking their drugs were more likely to have treatment failure.
"Another quite interesting finding was that being public about their HIV status was associated with suppression of virus," Ramadhani said. "There still is a substantial stigma associated with HIV in Africa. It is likely that individuals infected with HIV who discussed their disease with friends or family members are likely living in supportive environments that promote adherence."
The researchers also found that the farther away patients were from the clinic, the less likely they would take their drugs as instructed.
"This study has identified critical factors that affect the success of antiretroviral therapy programs in Africa, and we believe that these findings should be incorporated by policy makers into practice," said Duke's John Crump, M.B., Ch.B, who specializes in infectious diseases and international health and is a senior member of the research team. "These drugs, which are known to work, should be free and readily available.
"Structural barriers to care, such as the distance to clinics and especially the burden of patients paying for their medication, must be removed," Crump continued. "Social coping, including the disclosure of HIV status to people to family and friends leads to better adherence to medication and lower rates of treatment failure."
According to Michael H., Merson. M.D., director of the Duke Global Health Institute, "This study nicely illustrates some of the factors that need to be considered in reducing the health disparities between the haves and have nots throughout the world, and the value of exploring ways to eliminate them through a multidisciplinary lens. Reducing costs, increasing access and lessening stigma are all necessary for providing good AIDS treatment."
Duke University Medical Center
HIV Current Events and HIV News RSSSelenium may slow march of AIDS
Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists.
ACP recommends routine HIV screening for all patients
On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org.
Study of ancient and modern plagues finds common features
In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta.
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
More at-risk teens and young adults engaging in anal intercourse
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex.
Landmark study defines benefits of early HIV testing and treatment for infected infants
Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
First Holistic Guide to Primate Disease Covers Critical Gap in Global Health
Why are so many infectious diseases jumping from animals to humans? Why do we have so little capacity to predict epidemics, or avoid them?
Applying 'supply and demand' business principles to treat infectious diseases worldwide
Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.
More HIV Current Events and HIV News Articles
 | 100 Questions and Answers About HIV and AIDS by Joel Gallant |
 | The First Year: HIV: An Essential Guide for the Newly Diagnosed (First Year, The) by Brett Grodeck This supportive resource explores the next generation of HIV/AIDS drugs and also includes new research on HIV and crystal meth, as well as new insights for the hardest hit population — African... |
 | The Guide to Living with HIV Infection: Developed at the Johns Hopkins AIDS Clinic (A Johns Hopkins Press Health Book) by John G. Bartlett, Ann K. Finkbeiner The Guide to Living with HIV Infection is the most complete source of medical, emotional, social, and practical advice available for those infected with HIV and their loved ones. Developed at the Johns Hopkins AIDS Clinic, the guide provides essential information for making decisions about treatment and testing in a world transformed by new research and pharmacotherapy.In this thoroughly updated... |
 | HIV/AIDS: A Very Short Introduction (Very Short Introductions) by Alan Whiteside HIV/AIDS is without doubt the worst epidemic to hit humankind since the Black Death. As of 2004 an estimated 40 million people were living with the disease, and about 20 million had died. Despite rapid scientific advances there is still no cure and the drugs are expensive and toxic. In the developing world, especially in parts of Africa, life expectancy has plummeted to below 35 years, causing... |
| Medical Management Of HIV Infection 2007 by John G. Bartlett, Joel E., M.D. Gallant | |
 | Healing HIV: How To Rebuild Your Immune System by Jon D., M.D. Kaiser, Jon D. Kaiser |
 | The Naked Truth: Young, Beautiful, and (HIV) Positive by Marvelyn Brown, Courtney E. Martin The surprisingly hopeful story of how a straight, nonpromiscuous, everyday girl contracted HIV and how she manages to stay upbeat, inspired, and more positive about life than ever before At nineteen years of age, Marvelyn Brown was lying in a stark white hospital bed at Tennessee Christian Medical Center, feeling hopeless. A former top track and basketball athlete, she was in the best shape of... |
 | The Cure For HIV / AIDS by Hulda, R. Clark Including new research and findings showing what the true causes of HIV & AIDS are and lead directly to their cure! 53 CURED Cases The First Year Cure, not treatment, is the subject of this book. In 1991 Dr Clark discovered the source of HIV. Once the source became clear the cure became obvious. but would it work? After curing 53 cases in a row, all who used this method, Dr Clark could wait no... |
 | HIV/AIDS and Society in South Africa We have not yet unravelled how HIV/AIDS is changing South Africa's social fabric, despite the fact that over 5 million South Africans are living with the virus. Do we know how HIV/AIDS may affect different sectors of society, possibly altering the course set for development? Is it possible that the way in which the epidemic is being fought - through health and human rights activism - is adjusting... |
 | Global HIV/AIDS Medicine HIV/AIDS management poses many different challenges around the world, and the therapies available in the West are often not economically feasible in developing countries. This new book is the first to address the myriad of clinical difficulties faced by health practitioners worldwide in managing HIV/AIDS. Edited by the same authorities responsible for the highly respected reference "The Medical... |
| © 2008 BrightSurf.com |